CancerNext
Guideline-based germline hereditary cancer panel.
- Developer
- Ambry Genetics
- Intended use
- Hereditary Cancer
- Cancer scope
- Not reported
- Specimen
- Whole blood
- Molecular modality
- DNA mutation
- Current version
- CancerNext current 41-gene panel (2026)
- Evidence context
- 0 structured studies · 0 indexed performance results · 1 sources
Why can reported performance numbers differ? MDI keeps each result attached to its study, population, stage or stratum, test version and source rather than treating performance as a fixed property of the test.